Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 90

Report ID: 1416

Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.
Asia Pacific is expected to be the fastest growing market owing to the availability of skilled professional such as ophthalmologist, and eye surgeons. Additionally, improving healthcare infrastructure in developing countries like India is further fuelling the growth of juvenile macular degeneration market. China and India contribute to the growth of the market.
In 2018, the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Juvenile Macular Degeneration (Stargardt Disease) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Juvenile Macular Degeneration (Stargardt Disease) Treatment development in United States, Europe and China.

The key players covered in this study
Sanofi
Bayer
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate

Market segment by Type, the product can be split into
Stem Cell Therapy
Gene Therapy
Others

Market segment by Application, split into
Hospitals
Eye Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Juvenile Macular Degeneration (Stargardt Disease) Treatment status, future forecast, growth opportunity, key market and key players.
To present the Juvenile Macular Degeneration (Stargardt Disease) Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Juvenile Macular Degeneration (Stargardt Disease) Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Stem Cell Therapy
1.4.3 Gene Therapy
1.4.4 Others
1.5 Market by Application
1.5.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Eye Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size
2.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Growth Trends by Regions
2.2.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions (2014-2025)
2.2.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Manufacturers
3.1.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue by Manufacturers (2014-2019)
3.1.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players Head office and Area Served
3.3 Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Product/Solution/Service
3.4 Date of Enter into Juvenile Macular Degeneration (Stargardt Disease) Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2014-2019)
4.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2014-2019)

5 United States
5.1 United States Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2014-2019)
5.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in United States
5.3 United States Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
5.4 United States Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

6 Europe
6.1 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2014-2019)
6.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Europe
6.3 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
6.4 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

7 China
7.1 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2014-2019)
7.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in China
7.3 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
7.4 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

8 Japan
8.1 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2014-2019)
8.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Japan
8.3 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
8.4 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2014-2019)
9.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Southeast Asia
9.3 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
9.4 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

10 India
10.1 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2014-2019)
10.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in India
10.3 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
10.4 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

11 Central & South America
11.1 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2014-2019)
11.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Central & South America
11.3 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type
11.4 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

12 International Players Profiles
12.1 Sanofi
12.1.1 Sanofi Company Details
12.1.2 Company Description and Business Overview
12.1.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.1.4 Sanofi Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.1.5 Sanofi Recent Development
12.2 Bayer
12.2.1 Bayer Company Details
12.2.2 Company Description and Business Overview
12.2.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.2.4 Bayer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.2.5 Bayer Recent Development
12.3 Roche
12.3.1 Roche Company Details
12.3.2 Company Description and Business Overview
12.3.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.3.4 Roche Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.3.5 Roche Recent Development
12.4 Pfizer
12.4.1 Pfizer Company Details
12.4.2 Company Description and Business Overview
12.4.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.4.4 Pfizer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.4.5 Pfizer Recent Development
12.5 Allergan
12.5.1 Allergan Company Details
12.5.2 Company Description and Business Overview
12.5.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.5.4 Allergan Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.5.5 Allergan Recent Development
12.6 Gilead Sciences
12.6.1 Gilead Sciences Company Details
12.6.2 Company Description and Business Overview
12.6.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.6.4 Gilead Sciences Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.6.5 Gilead Sciences Recent Development
12.7 Kubota Pharmaceutical
12.7.1 Kubota Pharmaceutical Company Details
12.7.2 Company Description and Business Overview
12.7.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.7.4 Kubota Pharmaceutical Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.7.5 Kubota Pharmaceutical Recent Development
12.8 Alkeus Pharmaceuticals
12.8.1 Alkeus Pharmaceuticals Company Details
12.8.2 Company Description and Business Overview
12.8.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.8.4 Alkeus Pharmaceuticals Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.8.5 Alkeus Pharmaceuticals Recent Development
12.9 Astellas Pharma
12.9.1 Astellas Pharma Company Details
12.9.2 Company Description and Business Overview
12.9.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.9.4 Astellas Pharma Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.9.5 Astellas Pharma Recent Development
12.10 Ferrer Corporate
12.10.1 Ferrer Corporate Company Details
12.10.2 Company Description and Business Overview
12.10.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
12.10.4 Ferrer Corporate Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2014-2019)
12.10.5 Ferrer Corporate Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details